Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
16 shown of 6,715 total abstracts
  1. Abstract 103902026-06-03 · 13:30 CT · S406
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-543
    C. Saura, J. Brahmer · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
  2. Abstract 103502026-06-05 · 21:15 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    T. Mok, N. Rizvi, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  3. Abstract 100822026-06-02 · 19:15 CT · Hall B1
    CheckMate-179: Opdivo (nivolumab) maintenance in metastatic melanoma
    M. Reck, J. Brahmer, T. Mok, et al. · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  4. Abstract 95682026-06-02 · 16:00 CT · E450
    CheckMate-303: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    A. Spira, C. Saura, M.C. Garassino, et al. · Chinese University of Hong Kong
    Poster Discussion SessionMelanoma📄🖼️
  5. Abstract 99462026-06-03 · 13:30 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-383
    S. Tolaney, S. Antonia · National Cancer Center Japan
    Poster Discussion SessionMelanoma📄🖼️
  6. Abstract 102742026-06-02 · 14:45 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-875
    A. Spira, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  7. Abstract 100372026-06-01 · 13:30 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-529
    P. Schmid, L. Paz-Ares · Mayo Clinic
    Poster Discussion SessionMelanoma📄🖼️
  8. Abstract 100182026-06-01 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-573 study)
    E. Winer, M.C. Garassino, N. Rizvi, et al. · Karolinska Institute
    Poster Discussion SessionMelanoma📄🖼️
  9. Abstract 97092026-06-03 · 16:45 CT · E450
    CheckMate-872: Opdivo (nivolumab) 2L in metastatic melanoma
    M.C. Garassino, H. Rugo, E. Winer, et al. · MD Anderson Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  10. Abstract 101382026-06-01 · 18:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-871
    S. Tolaney, E. Winer, R. Herbst, et al. · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  11. Abstract 100942026-06-02 · 20:00 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-229 study)
    J. Brahmer, F. Andre, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  12. Abstract 101012026-06-01 · 21:00 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    M. Reck, T. Mok, E. Winer, et al. · Institut Gustave Roussy
    Poster Discussion SessionMelanoma📄🖼️
  13. Abstract 97902026-06-05 · 20:00 CT · S100A
    Long-term follow-up of Opdivo neoadjuvant for metastatic melanoma: CheckMate-655
    E. Winer, M.C. Garassino, C. Saura, et al. · Institut Gustave Roussy
    Poster Discussion SessionMelanoma📄🖼️
  14. Abstract 101242026-06-04 · 20:30 CT · S100A
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-905
    S. Tolaney, J. Brahmer, A. Spira, et al. · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  15. Abstract 101452026-06-01 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-14 study)
    H. Rugo, J. Brahmer, T. Mok · National Cancer Center Japan
    Poster Discussion SessionMelanoma📄🖼️
  16. Abstract 98972026-06-04 · 18:45 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    S. Peters, H. Rugo, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.